Natural Killer (NK) Cell for Immunotherapy Development
The unique properties of NK cells open up a new arena of novel cell-based immunotherapy against cancers. With our advanced technology platforms and extensive experience, Creative Biolabs can provide powerful risk-based preclinical data verification services to help the development of natural killer (NK) cell therapy.
Natural Killer (NK) Cells
Natural killer (NK) cells are part of the innate immune system and can spontaneously kill malignant cells (cancer, foreign or virus-infected cells) in a non-specific manner without prior sensitization, hence the designation "natural" killers. Thus, NK cells play critical roles in host immunity against cancer. NK cells can be derived from various sources and can be obtained from the patient (autologous setting) or a healthy donor (allogeneic setting). The inherent qualities of NK cells, their rapid killing, and broad cytotoxicity make them promising candidates uniquely primed for immunotherapy to exploit NK cell anti-tumor properties in the clinic.
NK Cell Therapy
Diverse approaches for NK cell therapy encompass the development of large-scale NK cell-expansion protocols for the adoptive transfer of unmodified autologous or allogeneic NK cells. First is the establishment of a microenvironment favorable to NK cell activity and immunosuppression, which should be explored in combination with NK cell adoptive therapy. Second is the redirection of NK cell activity against tumor cells and the release of inhibitory signals that limit NK cell function. Given the donor-dependent variability of the NK cell yield and the efficiency in recognizing and killing targets, NK cell lines represent an easy and attractive tool for adoptive cellular therapy. NK cell therapy is applicable for patients with refractory leukemia or various forms of cancer, but its current use has been focused primarily on hematologic malignancies.
Fig.1 Therapy with the adoptive transfer of NK cells. (Guillerey, 2016)
Our Service for NK Cell Therapy
Several approaches targeting NK cells are currently in clinical or preclinical development, and most of these have an excellent safety profile. Although NK cell therapy is promising, there are still some limitations that need to be overcome, including insufficient cell numbers in vivo, restricted homing to tumor sites, and effector hampered function.
Based on the outstanding expertise and rich experience, Creative Biolabs is dedicated to providing professional drug development consulting services for NK cell therapy research. Our powerful risk-based consulting platform focuses on project assessment, preclinical and clinical drug development. We serve our clients with the most reliable and qualified results to help you make an early decision about your project thus reducing investment risk.
NK cell-based immunotherapy holds great promise for cancer treatment and Creative Biolabs is our customer's ideal partner for risk-based project assessment. If you are interested in our services, please contact us with the requirement of the project and your specific needs.
Guillerey, C.; et al. Targeting natural killer cells in cancer immunotherapy. Nature immunology. 2016, 17(9): 1025.